Recently in 2024, the agency received a report involving a patient who received the nasal solution as an injection.

(Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today ...

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and ...

INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray) INDICATION neffy 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis ...

has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country.

In early August, the FDA approved neffy epinephrine nasal spray to treat emergent type 1 allergic reactions in patients who weigh at least 66 pounds. The approval was based on four studies of 175 ...

ARS Pharmaceuticals, Inc. has announced the filing for approval of neffy® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy®. This follows ...

unaudited neffy ® (epinephrine nasal spray) net product revenue for the fourth quarter and full year 2024 and outlined its 2025 commercial and clinical objectives. “For ARS Pharma, 2024 marked ...